OBJECTIVES: Platelet glycoprotein IIb/IIIa inhibitors (GPI) are utilized predominantly in patients undergoing percutaneous coronary intervention (PCI); they include the small molecules eptifibatide and tirofiban, and the monoclonal antibody abciximab. Each has bolus and infusion regimens. Clinical trials in product information have 12-24 hour minimum infusion requirements; however, bolus only or shorter infusion regimens have been explored to reduce pharmacy costs. This analysis examines 2015 eptifibatide purchasing to determine the ratio of smaller (bolus) vials to larger (infusion) vials and explore utilization patterns in contemporary hospital practice. METHODS: The Source Healthcare Analytic database was queried for available 2015 months. Eptifibatide data were supplied with 10ML vials and the 100 ML assumed to be bolus and infusion vials respectively. Assuming eptifibatide was used exclusively in PCI patients, the expected ratio of bolus to infusion vials would be 2:2, an estimate based on the recommended dosing regimen of boluses, followed by the minimum 12 hour infusion in an 89 kg patient with normal renal function. Using 2015 wholesale acquisition costs (WAC) of bolus and infusion vials, a 2:2 regimen costs at least $1,336 per patient. RESULTS: Eptifibatide purchasing through November 2015 was 433,319 vials; 180,158 were bolus (42%) and 253,161 were infusion (58%); a ratio of 2:3. The purchases of infusion vials exceeded the expected ratio of 2:2 in the average PCI patient. Using WAC of bolus and infusion vials, per patient cost of the average regimen is at least $1,845, exceeding the expected $1,336. CONCLUSIONS: